Re: Francis et  al.: Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy (Ophthalmology. 2017;124:1788-1798)

We read with interest the work by Francis et  al,1 describing the clinical characteristics and OCT findings of a novel pathologic condition named mitogen-activated protein kinase (MEK) inhibitor-associated retinopathy (MEKAR). They explained that the toxicity profile of a novel class of chemotherapeutics that specifically blocks the mitogen-a ctivated protein kinase pathway includes the acute accumulation (within approximately 2 weeks from the first intake) of focal or multifocal, self-limited (approximately 32 days), nongravitational, subretinal fluid (SRF) pockets, distributed through the entire macula in one or both eyes.
Source: Ophthalmology - Category: Opthalmology Authors: Tags: Correspondence Source Type: research